An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade.

Trial Profile

An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Avacopan (Primary)
  • Indications IgA nephropathy
  • Focus Adverse reactions; Proof of concept
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 54th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress 2017, according to a ChemoCentryx Inc. media release.
    • 06 Jun 2017 Results published in a ChemoCentryx Inc. media release.
    • 19 Dec 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top